WO2014019830A1 - Transport de substances photosensibilisantes à l'aide de cellules immunes pour traiter des tumeurs - Google Patents

Transport de substances photosensibilisantes à l'aide de cellules immunes pour traiter des tumeurs Download PDF

Info

Publication number
WO2014019830A1
WO2014019830A1 PCT/EP2013/064716 EP2013064716W WO2014019830A1 WO 2014019830 A1 WO2014019830 A1 WO 2014019830A1 EP 2013064716 W EP2013064716 W EP 2013064716W WO 2014019830 A1 WO2014019830 A1 WO 2014019830A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
photosensitizer
immune cell
vivo
substance
Prior art date
Application number
PCT/EP2013/064716
Other languages
German (de)
English (en)
Inventor
Anja PHILIPPI
André-René BLAUDSZUN
Marc Schneider
Original Assignee
Kist Europe Korea Institute Of Science And Technology Europe Forschungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kist Europe Korea Institute Of Science And Technology Europe Forschungsgesellschaft Mbh filed Critical Kist Europe Korea Institute Of Science And Technology Europe Forschungsgesellschaft Mbh
Publication of WO2014019830A1 publication Critical patent/WO2014019830A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors

Definitions

  • the present invention relates to a modified mammalian immune cell for tumor treatment.
  • different methods are known. So is u.a.
  • immunotherapy is another approach in cancer therapy. It uses components of the immune system, such as antibodies, cytokines or immune cells, to fight tumor cells.
  • Immune cells have a natural ability to recognize and target the sites of infection and inflammation, or even tumor cells. This ability is also referred to as "homing.” Tumor cells have an altered proteome compared to healthy cells Proteins and peptides on the tumor cell surface act as tumor antigens, which can be specifically recognized by certain immune cells, eg T and B lymphocytes, whereas macrophages, neutrophils and NK cells recognize pathogens and cancer cells independently of tumor antigens.
  • the approach of cellular immunotherapy is to use immune cells to kill the body's own tumor cells.
  • the immune cells used are able to distinguish tumor cells from healthy cells.
  • DLI donor lymphocyte infusion
  • ACT adoptive cell transfer
  • DC vaccination dendritic cell vaccination
  • Nanoparticles which are provided with the substance to be transported, are bound to the surface of carrier cells. Depending on the cell type and the associated "homing" function, the cell arrives in vivo at its target and thus at the site of action for the corresponding substance.
  • PDT photodynamic therapy
  • the photosensitizing substance can be administered systemically or locally Even in the case of local application, the light-inducible substance is absorbed not only by tumor tissue but also by other organs such as the eyes and the skin it comes with light exposure of the patient n also to an
  • US 2002/0197262 A1 discloses, for the more specific transport of a photosensitizer, a method in which a photosensitizer is conjugated to an antibody. is bound by, which has tumor specificity. In this way, the photosensitizer reaches the tumor region.
  • the object of the present invention was to find a way to increase the specificity and effectiveness of photodynamic therapy, thereby reducing typical side effects.
  • the object is achieved by a modified mammalian immune cell which is loaded with a photosensitizing substance, wherein the photosensitizing substance is taken up in the immune cell.
  • loading of the immune cell means that the photosensitizing substance is taken up in the cell. If particles provided with a photosensitizing substance, such as nano- or microparticulate particles, are used, they too are enveloped by the membrane of the cell and in this way integrated into the cell. The uptake of the photosensitizing substance into the cell takes place via endocytosis and is also referred to as internalization.
  • an immune cell with a photosensitizing substance and thus combination of PDT and cellular immunotherapy, both the selectivity and efficiency of PDT are increased.
  • the photosensitizing substance is brought by the immune cell directly to the tumor cell and transferred to this.
  • the immediate interaction of the immune cell with the target tumor cell allows smaller amounts of the photosensitizing substance to be used more selectively than if the drug is administered to the patient intravenously / systemically or locally.
  • Targeted drug delivery and lower drug levels contribute to fewer side effects than traditional PDT in this approach.
  • immune cells also increases the efficiency of PDT.
  • the cells of the human defense system are characterized by the fact that they can detect disease foci and actively penetrate into malignant tissue. NEN. This natural homing function of immune cells should be exploited to promote photosensitizing substances targeted to the site of action.
  • many immune cells have the ability to kill diseased cells either by cytotoxic mechanisms or by phagocytosis.
  • the intrinsic cytotoxic function or phagocytic activity (“knocking" function) and thus cancer-killing effect of immune cells should be used to fight tumor cells as efficiently as possible
  • the intrinsic cytotoxic activity such as helper T cells, is given a type of cytotoxic function by the photosensitizing substance, which, by loading the immune cell with a photosensitizing substance, gives it a cytotoxic or intrinsic killing function Immune cell reinforced.
  • tumor or tumor cells are cancer cells or a multiplicity of cancer cells in a composite, such as malignant tissue.
  • the term cancer cell includes cells that undergo oncogenic proliferation.
  • photosensitizing substance is to be understood as meaning a chemical component or a precursor of a chemical component which causes a biological effect on the basis of photoactivation.
  • the photosensitizing substance is a photosensitizer, preferably a hematoporphyrin, chlorin, bacteriochlorin, phthalocyanine, benzoporphyrin derivative, 5-aminolevulinic acid (ALA) or esters, hypericin, purpurin, porphycene, indocyanine green (ICG ), as well as their derivatives.
  • a photosensitizer preferably a hematoporphyrin, chlorin, bacteriochlorin, phthalocyanine, benzoporphyrin derivative, 5-aminolevulinic acid (ALA) or esters, hypericin, purpurin, porphycene, indocyanine green (ICG ), as well as their derivatives.
  • the photosensitizing substance is a water-soluble photosensitizer complex, for example PSS / mTHPP or PSS / mTHPC, or a chemically modified photosensitizer.
  • the photosensitizing substance is a dendrimeric photosensitizer formulation, a photosensitizer-antibody conjugate, a photosensitizing nanoparticle, a liposomal photosensitizer formulation, or a nano- or microparticulate photosensitizer formulation.
  • the nano- or microparticulate photosensitizer formulation is preferably photosensitizer-gold particles, photosensitizer-PLGA particles or particles coated with a photosensitizer.
  • microparticles are particles having diameters of from 400 nanometers to 10 micrometers, and nanoparticles are particles having diameters from 1 to 400 nanometers. It is further preferred that the immune cell is loaded ex vivo by incubation with the photosensitizing substance, the uptake into the cell being by endocytosis.
  • mammalian immune cells To obtain mammalian immune cells, they must first be isolated from a tissue sample or blood. Subsequently, the isolated immune cell is preferably activated ex vivo and / or augmented ex vivo and / or generated ex vivo. Generated by ex vivo is understood to mean that this cell is differentiated into a derived immune cell type. Monocytes can e.g. be differentiated ex vivo to macrophages.
  • the immune cell is an autologous cell or an allogeneic cell.
  • a further object of the present invention is that the immune cell comprises a T lymphocyte, in particular an ex vivo activated and expanded polyclonal T cell, an ex vivo propagated tumor infiltrating T cell, an ex vivo expanded monoclonal antigen-specific T cell, a T cell Cell with a genetically engineered T cell receptor (TCR), or a genetically engineered is a chimeric antigen receptor (CAR) expressing T cell.
  • T lymphocyte in particular an ex vivo activated and expanded polyclonal T cell, an ex vivo propagated tumor infiltrating T cell, an ex vivo expanded monoclonal antigen-specific T cell, a T cell Cell with a genetically engineered T cell receptor (TCR), or a genetically engineered is a chimeric antigen receptor (CAR) expressing T cell.
  • TCR genetically engineered T cell receptor
  • CAR chimeric antigen receptor
  • the immune cell is a monocyte, in particular an autologous monocyte, a macrophage, in particular an autologous macrophage, a tumor-associated macrophage (TAM) or an in vitro-generated macrophage, a neutrophilic granulocyte, a natural killer cell (NK cell) and / or a cell an NK cell line, in particular an NK-92 cell and / or a CAR-expressing NK-92 cell.
  • a monocyte in particular an autologous monocyte
  • a macrophage in particular an autologous macrophage
  • TAM tumor-associated macrophage
  • TAM tumor-associated macrophage
  • NK cell natural killer cell
  • NK cell line in particular an NK-92 cell and / or a CAR-expressing NK-92 cell.
  • a modified immune cell is co-administered together with a retargeting substance, wherein the retargeting substance is preferably a bispecific antibody, diabody, BiTE antibody, trispecific antibody and / or tetraspecific antibody, and fragments which, acts.
  • the retargeting substance is preferably a bispecific antibody, diabody, BiTE antibody, trispecific antibody and / or tetraspecific antibody, and fragments which, acts.
  • monocytes, macrophages, NK cells and neutrophilic granulocytes can also be co-administered with one of the abovementioned retargeting substances.
  • the respective immune cell is pre-incubated with the corresponding retargeting substance immediately before administration. A immune cell functionalized with the retargeting substance is then administered.
  • T cells have receptors (T cell receptors, TCRs) that can recognize a particular peptide antigen bound to an MHC complex.
  • TCRs T cell receptors
  • an activated T cell is directed to a target cell, e.g. a cancer cell, which presents the corresponding peptide antigen MHC-dependent on its surface, binds the T cell with its T cell receptors to the antigen MHC complexes of the target cell. This specific recognition of the target cell triggers the effector function of the T cell.
  • CD8-positive cytotoxic T cells release perforin and granzyme, which drive the target cell into programmed cell death (cytolytic activity), while CD4-positive T cells secrete cytokines, thereby attracting other immune cells (helper function).
  • Ex vivo activated polyclonal T cells are not specific for a particular tumor antigen. As a result, they can detect the tumor focus, but it is theirs unable to bind to target cells and exert their natural effector functions.
  • a bispecific antibody which recognizes both the TCR component CD3 and is specific for a particular tumor antigen (e.g., EpCAM), cross-links MHC-independent nonspecifically activated T cells and cancer cells, triggering the cytolytic function of cytotoxic T cells.
  • tumor antigen e.g., EpCAM
  • Other T-cell subclasses, such as T-helper cells are also MHC-independently cross-linked to target cells via the bispecific antibody so that they can exert their effector functions.
  • the retargeting substance serves both the exact targeting and the stimulation of cytolytic activity and other functions of nonspecifically activated polyclonal T cells.
  • the antigen-specific recognition of target cells applies only to B and T cells. Macrophages and neutrophils recognize pathogens and cancer cells independent of antigen. If monocytes, macrophages, neutrophils or NK cells are used for the purposes of the present invention, it is advantageous to use a retargeting substance which primarily serves to target the immune cell used. Thus, bispecific antibodies can be used which recognize the Fcy receptors CD64 or CD16 expressed on monocytes, macrophages, neutrophilic granulocytes and NK cells and at the same time have a specificity for a tumor antigen.
  • the at least one modified immune cell is preferably used for cancer therapy on tumors on the body surface and / or on tumors that can be achieved in a minimally invasive manner, such as skin tumors, for example a basal cell carcinoma, malignant melanoma, head and neck carcinomas, bronchial and lung cancers , Bladder cancer, prostate carcinoma, colon carcinoma, liver carcinoma, Renal cell carcinoma, tumors of the female genital area, brain tumors or malignant ascites used.
  • skin tumors for example a basal cell carcinoma, malignant melanoma, head and neck carcinomas, bronchial and lung cancers , Bladder cancer, prostate carcinoma, colon carcinoma, liver carcinoma, Renal cell carcinoma, tumors of the female genital area, brain tumors or malignant ascites used.
  • a process for producing a modified mammalian immune cell is the subject of the present invention.
  • mammalian immune cells they are first isolated from a mammalian tissue sample or blood. Subsequently, the isolated immune cell is preferably activated ex vivo and / or augmented ex vivo and / or generated ex vivo. Generated ex vivo is to understand that the isolated immune cell is differentiated into a derived immune cell type. Thereafter, the loading of the immune cell is carried out with a photosensitizing substance, wherein the loading is carried out by incubation with the photosensitizing substance. Preferably, the immune cell is subsequently incubated with a retargeting substance, preferably a bispecific antibody.
  • a photosensitizing substance preferably a bispecific antibody.
  • the photosensitizing substance is a photosensitizer, preferably a hematoporphyrin, chlorin, bacteriochlorin, phthalocyanine, benzoporphyrin derivative, 5-aminolevulinic acid (ALA) or ester, hypericin, purpurin, porphycene, indocyanine green (ICG), and their derivatives, or a water-soluble photosensitizer complex, a chemically modified photosensitizer, a liposomal photosensitizer formulation, a nano- or microparticulate photosensitizer formulation, a dendrimeric photosensitizer formulation, a photosensitizer-antibody conjugate, and / or a photosensitizing nanoparticle ,
  • a photosensitizer preferably a hematoporphyrin, chlorin, bacteriochlorin, phthalocyanine, benzoporphyrin derivative, 5-aminolevulinic acid (ALA)
  • a modified immune cell is co-administered together with a retargeting substance, wherein the retargeting substance is preferably a bispecific antibody, diabody, BiTE antibody, trispecific antibody and / or tetraspecific antibody, and Fragments of these, acts.
  • the retargeting substance is preferably a bispecific antibody, diabody, BiTE antibody, trispecific antibody and / or tetraspecific antibody, and Fragments of these, acts.
  • the photosensitizing substance is transported with the help of immune cells targeted to the target site, the tumor focus, can lower amounts of substance as used in conventional photodynamic therapy. This should significantly reduce the side effects of PDT. Due to the additional cellular "killing" mechanisms of the immune cells, there is a significant increase in efficiency.
  • Fig. 2 Results of the determination of the viability of PSS / mTHPP-loaded T cells; 3 shows a fluorescence microscopic detection of the photosensitizer transfer of PSS / mTHPP-loaded T lymphocytes to cancer cells; and
  • Fig. 4 Results of the determination of the cytotoxic effect of PSS / mTHPP-loaded T cells.
  • FIG. 1 shows ex vivo activated human T lymphocytes which have taken up the photosensitizer complex PSS / mTHPP.
  • Ex vivo stimulated human T cells were incubated on the seventh day post-activation for 2 hours with a PSS / mTHPP amount corresponding to a mTHPP concentration of 10 g / ml.
  • the subcellular distribution of the photosensitizer mTHPP was analyzed by means of an inverse IX 71 fluorescence microscope (Olympus). The cell nuclei were detected by DAPI.
  • Figure A shows the individual fluorescent nuclei (N),
  • Figure B the fluorescence of the photosensitizer (P) and
  • Figure C the nuclear staining and photosensitizer fluorescence in one image.
  • FIG. 2 graphically shows the results of a viability test as performed in Embodiment 5.
  • FIG. 4 On the fourth (A) or third (B) day After activation, T lymphocytes were loaded with the photosensitizer complex PSS / mTHPP, or only ⁇ 2 ⁇ ⁇ was added to the control (uncharged T cells). Some of the samples were stored in the dark after loading. On the other hand, the remaining batches were irradiated either immediately (A) or after 72 hours (B) for 2 minutes with a calhalogen light source (h * v). At the times indicated, T-cell viability was determined. Triton ⁇ -100-treated T lymphocytes each served as a positive control. In each case triple measurements were carried out.
  • B C1, C2, C3: Samples 1, 2, 3.
  • Figure 3 shows in Figure A a nuclear staining of Skov-3 cells (SN) (human ovarian carcinoma cell line, ATCC, Manassas, USA) and loaded T cells (TN) as described in Example 4.
  • Skov-3 cells human ovarian carcinoma cell line, ATCC, Manassas, USA
  • TN loaded T cells
  • the fluorescence of the photosensitizer mTHPP is visible in the cells. By means of this fluorescence microscopy, the distribution of the photosensitizer can be documented.
  • the photosensitizer is also located in the tumor cells (P) and thus transferred from the loaded T lymphocytes (TNP) to the co-cultured Skov-3 cancer cells.
  • Fig. 4 graphically shows the cytotoxic effect of PS-loaded T lymphocytes on Skov-3 cells (human ovarian carcinoma cell line). After activation of the photosensitizer, by a total of three (3, 2.5 and 2 hours) irradiation of all batches before each measurement, a viability test was carried out at the indicated times. The experimental procedure is described in Example 6. This shows in the control samples of unloaded T cells and Skov-3 cells with medium alone Increase in cancer cell viabilitat. In the case of loaded T cells without bispecific antibodies as a retargeting substance, a similar decrease in cancer cell viabilitvity can be seen as in unloaded T cells with retargeting substance.
  • Human T lymphocytes are isolated from fresh buffy coat blood using the RosetteSep® Human T Cell Enrichment Cocktail (StemCell Technologies, Grenoble, France) according to the manufacturer's instructions. In each case 20 ml of blood are mixed with 0.5 ml of RosetteSep® antibody cocktail and incubated with gentle shaking for 20 min at room temperature. The mixture is then mixed with 10 ml of PBS (phosphate-buffered saline), carefully pipetted onto 15 ml Pancoll human (PAN Biotech, Aidenbach, Germany) and centrifuged for 20 min at 1200 * g with the brake off. The then enriched in the boundary layer between Pancoll and serum T cells are transferred to PBS and sedimented.
  • PBS phosphate-buffered saline
  • T cells After removal of residual erythrocytes with the aid of BD Pharm Lysis Lysing buffer (BD Biosciences, Heidelberg, Germany), the remaining T cells are washed twice more with PBS and finally in culture medium (RPMI 1640, PAN Biotech + 10% (v / v ) heat-inactivated FBS, PAN Biotech + 1% (v / v) penicillin / streptomycin, Sigma-Aldrich, Steinheim, Germany).
  • culture medium RPMI 1640, PAN Biotech + 10% (v / v ) heat-inactivated FBS, PAN Biotech + 1% (v / v) penicillin / streptomycin, Sigma-Aldrich, Steinheim, Germany).
  • the isolated T lymphocytes using the T-Cell Activation / Expansion Kit human (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
  • the cell concentration in culture medium is adjusted to 2.5 ⁇ 10 6 T cells / ml.
  • the cells are added in a ratio of 2: 1 with anti-CD3, anti-CD28 and anti-CD2 coupled microbeads and incubated for 72 hours in a water vapor-saturated 5% CO2 / air mixture at a temperature of 37 ° C.
  • the culture medium is removed and the cell density in fresh medium again adjusted to 2.5 ⁇ 10 6 T cells / ml.
  • the cultures are mixed with 20 U / ml of human Interleukin-2 (PAN Biotech) and cultured for one day at a temperature of 37 ° C in the CO2 incubator.
  • the T lymphocytes are subjected to another Pancoll density gradient centrifugation on the fourth day after activation by layering the cells resuspended in 20 ml of culture medium over 20 ml of Pancoll, and 20 After transferring the T cells enriched in the intermediate layer into PBS, they are sedimented again and taken up in culture medium.After cell count determination, the T lymphocytes are either used immediately for further experiments or at a cell density of 2.5 ⁇ 10 6 cells / ml in turn with 20 U / ml interleukin-2 and cultured for a further 1 -3 days at 37 ° C in a CO2 incubator.
  • the water-soluble photosensitizer PSS / mTHPP is used in this embodiment.
  • the water-soluble photosensitizer complex PSS / mTHPP which is present in lyophilised form is prepared with sterile H2OMIII P ore at a concentration of 5 mg / ml. The stock solution is kept protected from light for a maximum of two weeks at 4 ° C.
  • the cell density in culture medium RPMI 1640 + 10% FBS and 1% Pen / Strep
  • the cells are mixed with an amount of PSS / mTHPP stock solution corresponding to the respectively indicated mTHPP concentration and incubated for 2 hours at 37 ° C. in the CO 2 incubator.
  • the T lymphocytes are then washed three times with ice-cold culture medium. Thereafter, the cells are either immediately used for further use or taken up in IL-2-containing culture medium and further cultivated until their later use. Only T cells incubated with ⁇ 2 ⁇ d each served as a control (uncharged cells).
  • a Dukalux SL lamp (Kindermann GmbH, Ochsenfurt, Germany, emission max ⁇ 61 1 nm) is used in all work steps. To avoid premature activation of the light-inducible drug, the incubations are done in the dark.
  • a non-water-soluble photosensitizer is used, it is first dissolved in ethanol. The photosensitizer dissolved in ethanol is then added to the cell suspension and incubated with it.
  • T cells are incubated on the seventh day after activation with a PSS / mTHPP amount dissolved in H 2 O, which has a mTHPP concentration of 10 g / ml. ml corresponds.
  • PSS / mTHPP a PSS / mTHPP amount dissolved in H 2 O
  • mTHPP concentration 10 g / ml. ml corresponds.
  • the cells are subjected to fluorescence microscopic analysis.
  • 3 ⁇ 10 6 loaded T lymphocytes are first fixed for 10 min in 4% (w / v) paraformaldehyde (Sigma-Aldrich) solution.
  • the cells are embedded in FluorSave mounting medium (Calbiochem) which has been previously probed with 1 g / ml DAPI (Sig. ma-Aldrich) has been added.
  • FluorSave mounting medium Calbiochem
  • the samples are stored overnight protected from light at room temperature. Subsequently, the preparations are stored darkened at 4 ° C until microscopy.
  • an inverse IX 71 fluorescence microscope from Olympus, equipped with a digital camera (F-View II, Olympus) and the Cell P software (version 2.8, Olympus)
  • the internalized photosensitizer is visualized.
  • For viewing the cells preferably a 60x / 1 .42 oil immersion objective is chosen.
  • the subcellular distribution of the photosensitiser is preferably determined by means of a WG filter (excitation: 510-550 nm , Emission> 590 nm). The exposure times varied depending on the signal intensity.
  • T lymphocytes are loaded for three hours with a quantity of photosensitizer complex dissolved in ⁇ 2 ⁇ ⁇ , which corresponds to a mTHPP concentration of 45 g / ml.
  • 3 cells human ovarian carcinoma cell line, ATCC, Manassas, USA
  • Clear black 96-well plate (Greiner Bio-one)
  • the loaded T cells are added to the cancer cells in a 4: 1 ratio. The batches are then cultured at 37 ° C in the CO2 incubator.
  • the samples are washed three times with medium, removing most of the T cells from the batches. Thereafter, the cells are visualized for 20 min with 5 g / ml Hoechst dye (Invitrogen) to visualize the cell nuclei. Subsequently, the distribution of the photosensitizer is analyzed by means of an inverse Olympus IX 71 fluorescence microscope.
  • the photo sensitizer complex mTHPP is autofluorescent. The procedure is carried out as described under 3..
  • the procedure is preferably as follows. On the fourth or third day after the / nw 'fro-stimulating T-cells are incubated in culture medium having a dissolved in ⁇ 2 ⁇ ⁇ complex quantity corresponding to a mTHPP concentration of 10 g / ml, or only with H 2 O staggered (unloaded T cells). After transfer of the loaded and unloaded T lymphocytes in 96-well plates (2.5x10 5 T cells / well), half of the samples are stored in the dark. The remaining batches are illuminated either immediately or after a 72-hour incubation in the CO2 incubator.
  • T-cells treated with 1% (w / v) Triton X-100 can serve as positive controls.
  • the WST-1 assay measures the mitochondrial activity of cells, indicating their viability.
  • the test is based on the photometric detection of a formazan dye resulting from the reduction of a tetrazolium salt by living cells.
  • the viability tests proceed according to the manufacturer's instructions. In each case 100 ⁇ cell suspension with 10 ⁇ WST-1 reagent are added.
  • the absorption measurement is carried out in a Microplate reader (Spectra ELISA Reader, Tecan, Crailsheim, Germany) at a wavelength of 450 nm (reference wavelength: 690 nm). Triple measurements are carried out in each case.
  • the WST-1 assay can also be used, as described under 5.
  • T cells are incubated on the fourth day after activation loaded in ⁇ 2 ⁇ ⁇ , corresponding to a mTHPP concentration of 30 g / ml, or only incubated with H 2 O (uncharged T cells).
  • H 2 O uncharged T cells
  • 80,000 T lymphocytes loaded and unloaded are added to the cancer cells in triplicates, half of the batches are additionally supplemented with a retargeting substance, (human ovarian carcinoma cell line).
  • 0.1 g / ml bispecific antibody HEA125xOKT3 (Gerhard Moldenhauer, DKFZ Heidelberg, Germany) was added to Skov-3 cells treated with 1% (w / v) Triton X-100 as well as untreated cancer cells . Negative control serve. All preparations are incubated in the dark at 37 ° C and 5% CO2.
  • WST-1 assays (Roche Applied Science) are performed at the indicated times.
  • the photosensitizer is activated by irradiating all of the batches three times (3, 2.5, and 2 hours) under standard conditions with halogen light (Haloline Eco, 400 W, 9000 Im, OS RAM) for 2 minutes before each measurement.
  • the viability tests are carried out according to the manufacturer's instructions, as described under 5..
  • the absorption of 80,000 T-lymphocytes is subtracted from the respective values of the cocultures.
  • the modified immune cell After recovery of mammalian immune cells and subsequent activation and / or propagation and loading of the immune cell with a photosensitizing substance, the modified immune cell is preferably applied to a patient. Preferably, the modified immune cell is administered to the patient intravenously or locally.
  • a retargeting substance can be applied to photosensitizer-loaded To crosslink immune cells at the site of action with the target cells and thereby possibly trigger the intrinsic cytotoxic activity of the carrier cells.
  • the modified immune cells once they have reached the target site, first perform their natural "killing" function before, at a defined time, the photosensitizing substance is activated by light irradiation and thus additionally acts on the tumor cells tumors can be used in a single radiation session, but there is a possibility of repeated radiation treatment, as well as treatment with loaded immune cells and retargeting substance once or several times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une cellule immune mammalienne modifiée, destinée au traitement de tumeurs, ainsi que son utilisation et sa production. Selon l'invention, la cellule immune mammalienne modifiée est chargée avec une substance photosensibilisante. La substance photosensibilisante est incluse dans la cellule immune, qui la transporte ainsi vers la cellule tumorale. Le chargement de la cellule immune avec une substance photosensibilisante lui confère donc une fonction cytotoxique ou renforce la fonction cytotoxique intrinsèque de la cellule immune.
PCT/EP2013/064716 2012-08-03 2013-07-11 Transport de substances photosensibilisantes à l'aide de cellules immunes pour traiter des tumeurs WO2014019830A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201210107166 DE102012107166B4 (de) 2012-08-03 2012-08-03 Transport von photosensibilisierenden Substanzen mit Hilfe lebender Immunzellen zur Tumorbehandlung
DE102012107166.7 2012-08-03

Publications (1)

Publication Number Publication Date
WO2014019830A1 true WO2014019830A1 (fr) 2014-02-06

Family

ID=48790450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/064716 WO2014019830A1 (fr) 2012-08-03 2013-07-11 Transport de substances photosensibilisantes à l'aide de cellules immunes pour traiter des tumeurs

Country Status (2)

Country Link
DE (1) DE102012107166B4 (fr)
WO (1) WO2014019830A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112206221A (zh) * 2020-11-06 2021-01-12 大连理工大学 一种负载斑蝥素的巨噬细胞膜包封的金属有机框架纳米颗粒及其制备方法
CN114533888A (zh) * 2022-02-21 2022-05-27 同济大学 一种以细胞为载体的仿生载药系统及其制备方法和应用
CN115414478A (zh) * 2022-08-03 2022-12-02 长春理工大学 抗菌光响应复合材料的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100326A2 (fr) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies permettant de traiter un cancer a l'aide d'immunoconjugues de photosensibilisant et de therapies de combinaison
EP2098589A2 (fr) * 2008-02-15 2009-09-09 Kist-Europe Forschungsgesellschaft Mbh Procédé de modification de cellule immunitaire et dispositif de modification de cellule
WO2010059253A2 (fr) 2008-11-24 2010-05-27 Massachusets Institute Of Technology Procédés et compositions pour la délivrance localisée d'agents
WO2010118873A1 (fr) * 2009-04-17 2010-10-21 Kist-Europe Vecteur pour le transport d'organismes microbiologiques vers des foyers d'une maladie
WO2011150420A1 (fr) * 2010-05-28 2011-12-01 Baylor College Of Medicine Nanoparticules d'or modifiées à des fins thérapeutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010050227A1 (de) 2010-11-04 2012-05-10 Siemens Aktiengesellschaft Endoskop mit 3D-Funktionalität

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100326A2 (fr) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies permettant de traiter un cancer a l'aide d'immunoconjugues de photosensibilisant et de therapies de combinaison
US20020197262A1 (en) 2001-05-01 2002-12-26 Tayyaba Hasan Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
EP2098589A2 (fr) * 2008-02-15 2009-09-09 Kist-Europe Forschungsgesellschaft Mbh Procédé de modification de cellule immunitaire et dispositif de modification de cellule
WO2010059253A2 (fr) 2008-11-24 2010-05-27 Massachusets Institute Of Technology Procédés et compositions pour la délivrance localisée d'agents
WO2010118873A1 (fr) * 2009-04-17 2010-10-21 Kist-Europe Vecteur pour le transport d'organismes microbiologiques vers des foyers d'une maladie
WO2011150420A1 (fr) * 2010-05-28 2011-12-01 Baylor College Of Medicine Nanoparticules d'or modifiées à des fins thérapeutiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAURA C KENNEDY ET AL: "T cells enhance gold nanoparticle delivery to tumors in vivo", NANOSCALE RESEARCH LETTERS, vol. 6, no. 1, 1 January 2011 (2011-01-01), pages 283, XP055084271, ISSN: 1556-276X, DOI: 10.1182/blood-2006-04-017061 *
MI-RAN CHOI ET AL: "A Cellular Trojan Horse for Delivery of Therapeutic Nanoparticles into Tumors", NANO LETTERS, vol. 7, no. 12, 1 December 2007 (2007-12-01), pages 3759 - 3765, XP055084287, ISSN: 1530-6984, DOI: 10.1021/nl072209h *
STEINFELD U ET AL: "T lymphocytes as potential therapeutic drug carrier for cancer treatment", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 311, no. 1-2, 27 March 2006 (2006-03-27), pages 229 - 236, XP027972682, ISSN: 0378-5173, [retrieved on 20060327] *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112206221A (zh) * 2020-11-06 2021-01-12 大连理工大学 一种负载斑蝥素的巨噬细胞膜包封的金属有机框架纳米颗粒及其制备方法
CN112206221B (zh) * 2020-11-06 2021-10-15 大连理工大学 一种负载斑蝥素的巨噬细胞膜包封的金属有机框架纳米颗粒及其制备方法
CN114533888A (zh) * 2022-02-21 2022-05-27 同济大学 一种以细胞为载体的仿生载药系统及其制备方法和应用
CN115414478A (zh) * 2022-08-03 2022-12-02 长春理工大学 抗菌光响应复合材料的制备方法
CN115414478B (zh) * 2022-08-03 2023-09-22 长春理工大学 抗菌光响应复合材料的制备方法

Also Published As

Publication number Publication date
DE102012107166A1 (de) 2014-05-22
DE102012107166B4 (de) 2015-04-30

Similar Documents

Publication Publication Date Title
KR102081666B1 (ko) 암 치료용 약학 조성물
WO2015188570A1 (fr) Composé de vert d'indocyanine, d'albumine et de paclitaxel, son procédé de préparation et son utilisation
DE69433590T2 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
JP2017532340A (ja) 光線力学療法、ｘ線誘起光線力学療法、放射線療法、化学療法、免疫療法、及びこれらの任意の組み合わせのためのナノ粒子
KR101188979B1 (ko) 광역학 진단 또는 치료를 위한 생체 적합성 고분자와 광감작제의 결합체 및 이의 제조방법
Zhao et al. Multifunctional magnetic nanoparticles for simultaneous cancer near-infrared imaging and targeting photodynamic therapy
DE102012107166B4 (de) Transport von photosensibilisierenden Substanzen mit Hilfe lebender Immunzellen zur Tumorbehandlung
Choe et al. Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery
CN114404571A (zh) 一种装载化疗药物且tigit过表达的工程化载药细胞膜囊泡以及制备方法和应用
WO2021083370A1 (fr) Préparation et utilisation d'un nanomatériau activant spécifiquement le système immunitaire
DE60017201T2 (de) Rhodaminderivate für die photodynamische diagnose und behandlung
Obochi et al. Targeting activated lymphocytes with photodynamic therapy: susceptibility of mitogen‐stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitization
DE60116075T2 (de) Behandlung von tumoren mit photodynamischer therapie
DE102004054536A1 (de) Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
JP7436993B2 (ja) 光発熱性複合材料、ナノクラスター、物質送達担体及び医薬組成物
US20230285457A1 (en) Nanoparticles for cancer treatment
EP2322142B1 (fr) Nanoparticules biocompatibles magnétiques pour le traitement de glioblastomes
CN108210923B (zh) 一种荧光染料与考马斯亮蓝共结合的血清白蛋白纳米粒及其制备方法和在肿瘤诊疗中应用
Chen et al. Selective castration-resistant prostate cancer photothermal ablation with copper sulfide nanoplates
Korolev et al. Fluorescent Nanoagents for Biomedical Applications
EP1289562A2 (fr) Nouvelle preparation d'hypericine liee a des poly-n-vinylamides
Fischer et al. Biodistribution and inflammatory response of intracranial delivery of scintillating nanoparticles
Niknejad et al. Near-IR absorbing quantum dots might be usable for growth factor-based differentiation of stem cells
CH650154A5 (de) Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung.
CN108421039B (zh) 金纳米团簇组装体、靶标标记自组装材料和肿瘤药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736899

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13736899

Country of ref document: EP

Kind code of ref document: A1